Advances in the systemic treatment of cutaneous sarcomas.

about

Positive PD-L1 Expression Predicts Worse Outcome in Cutaneous Angiosarcoma.Kutane Sarkome.Cutaneous sarcomas.

P2860

Q38613118-F74F8B87-CFFC-4B84-BFE6-BA881AD170BA Q39357839-14010148-87A9-4198-92DF-BA4BCC42311A Q39357854-B3325BFE-5705-4117-BFE5-104DAFB92899

P2860

Advances in the systemic treatment of cutaneous sarcomas.

Item

http://www.wikidata.org/entity/Q38000872

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Advances in the systemic treatment of cutaneous sarcomas.

@en

type

Item

label

Advances in the systemic treatment of cutaneous sarcomas.

@en

prefLabel

Advances in the systemic treatment of cutaneous sarcomas.

@en

P1476

Advances in the systemic treatment of cutaneous sarcomas.

@en

P2093

Jason J Luke

http://www.w3.org/2001/XMLSchema#string

Mary Louise Keohan

http://www.w3.org/2001/XMLSchema#string

P2860

KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors

FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis

Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection

Cancer statistics, 2009

Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566.

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC stu

MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema

P304

173-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMINONCOL.2012.01.004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22484189

http://www.w3.org/2001/XMLSchema#string

P932

3882013

http://www.w3.org/2001/XMLSchema#string

Advances in the systemic treatment of cutaneous sarcomas.

about

P2860

P2860

Advances in the systemic treatment of cutaneous sarcomas.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932